GlassScriptPhysician profile
Petros Ayele
NPI 1720238868
$4,319.01
in general payments reported to CMS, 2019-2025
35 companies · $629 in 2025
The $629 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $912 · 2020: $768 · 2021: $844 · 2022: $313 · 2023: $378 · 2024: $473 · 2025: $629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,462 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,461.58 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $611.46 | 2020-2025 | Austedo, Austedo Xr, Austedo Xr |
| Lilly USA, LLC | $491.36 | 2019-2025 | Kisunla |
| Novo Nordisk INC | $427.83 | 2019-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $266.07 | 2019-2024 | |
| Astellas Pharma US INC | $227.90 | 2019-2023 | Veozah |
| Janssen Pharmaceuticals, INC | $195.24 | 2019-2021 | |
| Amgen INC. | $188.08 | 2025 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $167.66 | 2023-2024 | Lokelma, Farxiga |
| Avanir Pharmaceuticals, INC. | $159.58 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $157.47 | 2022-2024 | Ingrezza |
| Gilead Sciences, INC. | $149.61 | 2021-2025 | Biktarvy |
| Lundbeck LLC | $141.64 | 2023-2025 | Rexulti |
| Pfizer INC. | $137.00 | 2020-2023 | |
| Sunovion Pharmaceuticals INC. | $127.37 | 2019-2021 | |
| Cmp Pharma, INC. | $98.84 | 2020-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $87.51 | 2023 | Gemtesa |
| Mylan Specialty L.P. | $85.78 | 2019-2023 | Yupelri |
| Vifor Pharma, INC. | $80.29 | 2019-2021 | |
| Exact Sciences Corporation | $56.81 | 2024-2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $53.98 | 2021-2022 | |
| Melinta Therapeutics, LLC | $42.04 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.64 | 2020-2021 | |
| Neurelis, INC. | $39.39 | 2025 | Valtoco |
| Otsuka America Pharmaceutical, INC. | $39.32 | 2024 | Rexulti, Abilify Maintena |
| Redhill Biopharma INC. | $37.38 | 2020-2021 | |
| Ucb, INC. | $31.62 | 2021 | |
| Travere Therapeutics, INC. | $30.17 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.55 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $19.74 | 2023 | Eliquis |
| Eisai INC. | $19.69 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.62 | 2024 | |
| Vanda Pharmaceuticals INC. | $18.13 | 2022 | |
| Acadia Pharmaceuticals INC | $17.38 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.73 | 2024 | Xifaxan |
| Glaxosmithkline, LLC. | $15.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Petros Ayele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.